Investigating the relative contribution of obesity and glucose in the development of β-cell dysfunction
Year: 2016
Type: dissertation
Abstract: Insulin resistance and impaired insulin secretion are hallmark features that contribute to the development of hyperglycaemia in type 2 diabetes (T2D) and other complications such as kidney failure, stroke and cardiovascular disease.Obesity is considered to be one of the main drivers in expediting hyperglycaemia by inducing insulin resistance in the liver, muscle and fat.These defects place additional stress on the β-cell to increase insulin output to compensate for the prevailing glucose and over time, can result in declined β-cell function and T2D.Pre-clinical and clinical studies investigating interventions that reduce obesity in pre-diabetes have shown that the incidence of T2D can be attenuated by preserving β-cell function through enhanced insulin sensitivity.However, as obesity clearly induces hyperglycaemia, it has become inherently difficult to dissociate the relative contribution of each in the progression of impaired glucose tolerance (IGT) to T2D.Accordingly, the scope of this thesis was to use dietary and pharmacological interventions to determine the contribution of obesity and glucose in the development of metabolic defects associated with T2D, namely glucose intolerance, insulin resistance and β-cell dysfunction.The overall hypothesis was that both obesity and excess glucose contribute to these defects.In order to address the overall aim of this thesis, it was necessary to firstly characterise a pre-clinical model that does not rely on the presence of obesity to drive hyperglycaemia and subsequently, insulin resistance and β-cell dysfunction.We therefore utilised the phosphoenolpyruvate carboxykinase (PEPCK) transgenic rat, which is characterised by a 2-3 fold induction of PEPCK in the liver and kidney that leads to the impaired suppression of endogenous glucose production.Through the use of in vivo and in vitro experimental techniques, we show that the PEPCK transgenic rat develops defective glucose-stimulated insulin secretion in parallel with the worsening of glucose tolerance at 14 weeks of age, and that this is primarily due to the significant reduction in β-cell Glut2 gene expression and the inability of the constituents that make up the K + ATP channel, Sur1 and Kir6.2, to function properly.This defect in insulin secretion progressively worsens by 20 weeks due to the combination of β-cell dysregulation and reduced β-cell mass.
Author: Christos N. Joannides
Institutions: The University of Melbourne, Austin Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2607807650
